There is currently no approved pharmaceutical treatment for premature ejaculation. But there are several advertised products that claim to do the job. However, these products may leave an after effect, which could include numbing and burning sensations, with the other sex partner. But this new product is stealth in design, and performs with minimum partner transfer.
PSD502 is the name given to the test-product, whose formulation consists of two marketed drugs, lidocaine and prilocaine, dispensed by metered aerosol. PSD502 is applied locally when needed, is effective in five minutes, and lasts up to 2 hours.
The prevalence rate of premature ejaculation in Europe and the United States is about 30%, which is fairly steady compared to erectile dysfunction that rises with age. The National Health and Social Life Survey (NHSLS) data revealed this prevalence rate, which could be conceivably higher because of the number of men who don’t seek treatment.
Premature ejaculation is a condition that affects the male only. It lowers self-esteem, presents marital dysfunction, and contributes to a state of depression.